(Q36384559)

13 August 2017

0 references

1 reference

title

Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? (English)

1 reference

13 August 2017

1 reference

H M Oudemans-van Straaten

1

1 reference

13 August 2017

J P J Wester

2

1 reference

13 August 2017

A C J M de Pont

3

1 reference

13 August 2017

M R C Schetz

4

1 reference

13 August 2017

publication date

2 February 2006

1 reference

13 August 2017

published in

Intensive Care Medicine

1 reference

13 August 2017

volume

32

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

188-202

1 reference

The use of the activated clotting time for monitoring heparin therapy in critically ill patients

13 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00134-005-0044-Y

The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00134-005-0044-Y

Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge

21 January 2018

1 reference

12 December 2020

Continuous renal replacement therapy in critically ill patients: monitoring circuit function

1 reference

12 December 2020

Cultured human endothelial cells generate tissue factor in response to endotoxin

1 reference

12 December 2020

Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients

1 reference

12 December 2020

Nafamostat Mesylate as Anticoagulant in Continuous Hemofiltration and Continuous Hemodiafiltration

1 reference

12 December 2020

Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

1 reference

12 December 2020

Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy

1 reference

12 December 2020

The effect of heparin rinse on the biocompatibility of continuous veno-venous hemodiafiltration

1 reference

12 December 2020

A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD).

1 reference

12 December 2020

Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance

1 reference

12 December 2020

Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia

1 reference

12 December 2020

The Acute Dialysis Quality Initiative--part VI: access and anticoagulation in CRRT.

1 reference

12 December 2020

A novel anti-thrombotic heparinoid (ORG 10172) devoid of bleeding inducing capacity: A survey of its pharmacological properties in experimental animal models

1 reference

12 December 2020

[Comparison of the antithrombotic effects of heparin, enoxaparin and prostacycline in continuous hemofiltration]

1 reference

12 December 2020

Continuous hemofiltration and platelet function in critically ill patients.

1 reference

12 December 2020

Additional mechanisms of nafamostat mesilate-associated hyperkalaemia

1 reference

12 December 2020

Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study

1 reference

12 December 2020

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients.

1 reference

12 December 2020

Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration

1 reference

12 December 2020

Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays

1 reference

12 December 2020

Low-Molecular-Weight Heparin for Anticoagulation During Continuous Venovenous Hemofiltration—Reply

1 reference

12 December 2020

Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation.

1 reference

12 December 2020

Transfusion requirements during continuous veno-venous haemofiltration: -the importance of filter life.

1 reference

12 December 2020

Albumin priming does not prolong hemofilter life

1 reference

12 December 2020

Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation

1 reference

12 December 2020

Outcome of critically ill patients treated with intermittent high-volume haemofiltration: a prospective cohort analysis

1 reference

12 December 2020

Inhibition of tissue factor-factor VIIa by nafamostat mesilate; a reply to the rebuttal.

1 reference

12 December 2020

Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis

1 reference

12 December 2020

Antithrombin III deficiency during continuous venovenous hemodialysis

1 reference

12 December 2020

Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis.

1 reference

12 December 2020

The Protein C Pathway

1 reference

12 December 2020

CVVH in postoperative care of liver transplantation

1 reference

12 December 2020

A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF).

1 reference

12 December 2020

Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage

1 reference

12 December 2020

Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease

1 reference

12 December 2020

Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study

1 reference

12 December 2020

Hirudin in renal insufficiency

1 reference

12 December 2020

Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.

1 reference

12 December 2020

Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients

1 reference

12 December 2020

Possible strategies to prolong circuit life during hemofiltration: three controlled studies

1 reference

12 December 2020

TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

12 December 2020

Hemostasis activation markers in acute renal failure

1 reference

12 December 2020

Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial

1 reference

12 December 2020

Continuous veno-venous hemofiltration without anticoagulation in high-risk patients.

1 reference

12 December 2020

Is impaired renal function a contraindication to the use of low-molecular-weight heparin?

1 reference

12 December 2020

Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial

1 reference

12 December 2020

Impairment of citrate metabolism in acute hepatic failure

1 reference

12 December 2020

Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane

1 reference

12 December 2020

Heparin clearance during continuous veno-venous haemofiltration

1 reference

12 December 2020

Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study

1 reference

12 December 2020

Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

1 reference

12 December 2020

Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis

1 reference

12 December 2020

Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient

1 reference

12 December 2020

Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit

1 reference

12 December 2020

Short- and long-acting synthetic pentasaccharides

1 reference

12 December 2020

Anticoagulation in continuous renal replacement therapy

1 reference

12 December 2020

Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans

1 reference

12 December 2020

The heparin-protamine interaction. A review.

1 reference

12 December 2020

Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin

1 reference

12 December 2020

A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions

1 reference

12 December 2020

Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.

1 reference

12 December 2020

Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study

1 reference

12 December 2020

Dose determinants in continuous renal replacement therapy

1 reference

12 December 2020

Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

12 December 2020

Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients

1 reference

12 December 2020

Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure.

1 reference

12 December 2020

Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial

1 reference

12 December 2020

Protamine-heparin aggregates. Their fine structure, histochemistry, and renal deposition

1 reference

12 December 2020

Kidney failure associated with liver transplantation or liver failure: the impact of continuous veno-venous hemofiltration

1 reference

12 December 2020

Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control

1 reference

12 December 2020

Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months

1 reference

12 December 2020

Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial.

1 reference

12 December 2020

A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease

1 reference

12 December 2020

Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.

1 reference

12 December 2020

Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study

1 reference

12 December 2020

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

1 reference

12 December 2020

Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure

1 reference

12 December 2020

A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration

1 reference

12 December 2020

Effect of anticoagulation on blood membrane interactions during hemodialysis

1 reference

12 December 2020

Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways

1 reference

12 December 2020

Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration

1 reference

12 December 2020

Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration.

1 reference

12 December 2020

Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis

1 reference

12 December 2020

Hemostatic alterations during continuous venovenous hemofiltration in acute renal failure

1 reference

12 December 2020

Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent

1 reference

12 December 2020

Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients

1 reference

12 December 2020

The therapeutic value of vasodilator prostaglandins in multiple organ failure associated with sepsis

1 reference

12 December 2020

The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit.

1 reference

12 December 2020

Continuous venovenous hemofiltration without anticoagulation

1 reference

12 December 2020

Extracorporeal management of acute renal failure patients at high risk of bleeding

1 reference

12 December 2020

Tissue factor is expressed on monocytes during simulated extracorporeal circulation

1 reference

12 December 2020

Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience.

1 reference

12 December 2020

Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Socie

1 reference

12 December 2020

Regional filter heparinization for continuous veno-venous hemofiltration in liver transplant recipients

1 reference

12 December 2020

Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration

1 reference

12 December 2020

Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostate mesilate

1 reference

12 December 2020

Hirudin versus heparin for anticoagulation in continuous renal replacement therapy.

1 reference

12 December 2020

Bleeding after intermittent or continuous r-hirudin during CVVH.

1 reference

12 December 2020

Influence of coagulation parameters on filter running time during continuous venovenous hemofiltration

1 reference

12 December 2020

Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation

1 reference

12 December 2020

Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration

1 reference

12 December 2020

Predilution versus postdilution for continuous arteriovenous hemofiltration

1 reference

12 December 2020

Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients.

1 reference

12 December 2020

More on anticoagulation for continuous hemofiltration

1 reference

12 December 2020

Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients

1 reference

12 December 2020

Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate.

1 reference

12 December 2020

Blood flow reductions during continuous renal replacement therapy and circuit life.

1 reference

12 December 2020

10.1007/S00134-005-0044-Y

Identifiers

DOI

1 reference

13 August 2017

1 reference